Objective: This study aimed to develop an autologous heart valve without using any traditional in vitro tissue-engineering methods, which necessitate complicated cell management protocols under exceptionally clean laboratory facilities.
INTRODUCTION
Prosthetic valve-replacement operations are currently regarded as the standard treatment for end-stage heart valve diseases; however, several clinical problems resulting from the use of these artificial valves exist. Lifetime anticoagulation therapy is necessary in the case of mechanical valves (1) (2) (3) (4) while the structure of the xenogeneic valvular leaflets gradually deteriorates in the case of bioprosthetic valves.(5-7) Both types of prosthetic valves are unsuitable for pediatric patients due to a lack of their ability to grow. (4) In recent developmental studies, to acquire the characteristics of enhanced maturation such as anticoagulation, self-repair, tissue regeneration, and adaptability to growth, autologous valve prostheses have been developed by using in vitro tissue-engineering technology. (8) (9) (10) (11) Some investigators have succeeded in the implantation of the in vitro tissue-engineered heart valves in animals and humans by using scaffolds based on either decellularized natural tissues or biodegradable synthetic polymers. (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) However, it is difficult to fabricate reproducible valves with a certain level of maturity.
For the development of autologous prosthetic tissues, we have embarked on a novel and practical concept in regenerative medicine, namely, the in body tissue architecture technology, which is based on the tissue-encapsulation phenomenon of foreign materials in living bodies. (22) (23) (24) The use of a recipient's body to construct organ tissues had been pioneered by Sparks and colleagues, who constructed arterial bypass grafts in recipients' subcutaneous spaces. In 1968, they clinically applied the silicone mandril method to arterial bypass. (25, 26) Similarly, Campbell successfully constructed arterial grafts in the peritoneal cavity of animals using silastic tubes. (27, 28) For in vivo cell seeding in bovine pericardium, Flameng and colleagues also utilized foreign body reaction through intraperitoneal implantation. (29, 30) This technique has the following advantages: the prostheses induce no immunological rejection; they exhibit nontoxic biocompatibility; and they might adapt to the recipient's growth. In addition, the tissue prostheses can be fabricated in a wide range of shapes and sizes to suit each individual recipient. Most importantly, neither complex cell management in vitro nor exceptionally clean laboratory facilities are required, both of which -3 -are expensive and time consuming.
The purpose of this study was to develop an autologous heart valve substitute by a more convenient and undemanding, compared to the traditional in vitro tissue engineering technique. We hereby describe, firstly, a fabrication method for the valvular structure named Biovalve, by using a specially designed mold. Subsequently, the results of examining the mechanical and histological properties of the Biovalve are described. In addition, we discuss the potential and limitations of the Biovalve.
METHODS

Preparation and Characterization of the Biovalve.
The molds were specially designed by covering a silicone rod with a crown-shaped tubular segmented polyurethane scaffold consisting of 3 isosceles triangular horns having a microporous wall structure (internal diameter of the scaffold, 5 or 20 mm; wall thickness, 1 or 
Physical Properties of the Biovalves.
Measurements of the thickness and tensile strength of the Biovalve leaflets were performed using a tensile strength machine (RE-3305; Yamaden Co., Ltd., Tokyo, Japan).
The specimens (size, 5 mm × 10 mm) were stress-loaded to rupture at a rate of 0.5 mm per second. The tensile strength denoted the amount of force required for rupture to occur.
The apparent elastic modulus was determined as the slope of the initial linear section of the stress-strain curve.
Regurgitation of the Biovalves was measured for a period of 1 minute under static pressure in a closed structure, 5 mm in size, using a specially designed flow-loading circuit that was capable of generating hydrostatic pressure by altering the revolutions of the roller pump (pressure, 12-200 mm Hg). The degree of regurgitation was estimated by the ratio of the regurgitation volume to the forward flow volume.
RESULTS
After placement of the specially designed molds (Fig. 1A) into the subcutaneous pouches for 4 weeks, they became completely encapsulated with the newly developed -5 -membranous connective tissues (Fig. 1B) . The implants could be easily harvested by cutting the surrounding tissues because the newly developed connective tissues and the original subcutaneous tissues were connected by very fragile irregular redundant tissues. Connective tissues were also formed in between the 3 horns of the crown-shaped scaffold. The membranous tissues were thin and homogenous in nature. After withdrawing the inserted silicone rod, the tubular connective tissue structure embedded within the scaffold was obtained. Biovalves were obtained after cutting of the membranous tissue formed between the horns into the predesigned shape. By changing the size of the mold, two different kinds of the Biovalves, with an internal diameter of either 5 or 20 mm were obtained (Fig. 1C) .
The larger Biovalve may fit adult human aortic valves.
In longitudinal sections of the Biovalve, it was observed that the luminal surface at the border between the leaflet structure and the scaffold was extremely smooth without any seam ( Fig. 2A) . Coaptation and opening of the leaflets were well-balanced ( Fig. 2B and C) .
Histologic analysis confirmed that in circumferential sections, the leaflets and polyurethane crowns were tightly connected to each other and unified with the same newly-formed connective tissues ( Fig. 3A and C) . The thickness of the leaflets was about 200 μm.
Interestingly, rich angiogenesis was induced near the scaffold (Fig. 3B ).
EVG staining revealed the absence of elastic fibers in the membranous leaflet tissue: however, rich collagen fibers were present ( Figure 4A ). Immunohistochemistry In this study, a microporous polyurethane tube cut into a simple crown shape was prepared as a scaffold. Polyurethanes, which are clinically used in blood pumps and arterial grafts, exhibited no toxicity and little biodegradation in vivo. (37, 38) With regard to the use of the polyurethane, we have demonstrated its good biocompatibility in a discrete series of experiments using dogs and rabbits. In these experiments, no anomalous accumulation of inflammatory cells around the scaffolds was observed during the fourth week; this observation was also demonstrated in this study (Fig. 3) . In addition, rapid and homogenous tissue infiltration was observed in the deep layer of the scaffolds. In the next stage of our research, we are planning the use of biodegradable scaffold materials so that attainment of proper adaptability for the growth of the tissue is possible. To form membranous tissues as leaflet parts between the horns of the scaffolds, silicone rods were inserted into the scaffolds in this study. Since the encapsulating tissues did not adhere to the silicone molds, the Biovalve leaflets could be easily obtained by extracting the rods and trimming away the redundant tissues.
In the histological examinations, the extracellular matrix of the Biovalve leaflets -8 -was observed to be mainly composed of collagen fibers (Fig. 3, 4A ). We could not reproduce exactly the same components of the native aortic valves, such as elastin, which is one of the major extracellular matrix proteins. However, it is presumed that maturation into highly differentiated tissues including those demonstrating elastic fiber formation could be induced under the mechanical stresses of pulsatile blood pressure and the opening and closing movements after implantation in the hemodynamic conditions in vivo. Indeed, in our implantation study on small-caliber tubular prostheses known as Biotubes, which were developed by the application of the in body tissue architecture technology, hierarchical vascular structure formation including the regeneration of elastic fibers was observed at 3 months after the implantation. (36) Another structural difference between the Biovalves and the native valves was that their blood-contacting surface was thrombogenic in nature. However, upon implantation in vivo, natural antithrombogenecity could be obtained rapidly as discussed below. In animal experiments using Biotubes coated with nonthrombogenic agents such as argatroban, graft patency was excellent and complete endothelialization was induced within 2 weeks. (30) Therefore, implanted Bivalves are also expected to be completely covered with endothelial cells forthwith. We could control the strength and thickness of the regenerated membranous tissues to a certain degree by changing the size of the molds (Table 1) . When we used a lager mold, the thickness of the membranous tissues increased and the tissues became stronger.
In regurgitation tests, the Biovalves showed high resistance to retrograde pressure (Fig 6) . Even the 5-mm Biovalves endured 100 to 200 mm Hg hydrostatic pressures.
Since the 20-mm Biovalves demonstrated better mechanical properties in strength or extensibility than the 5-mm Biovalves, we suggested that they also could sustain the high pressure extant in the arterial system.
We have created functional prototype models of autologous heart valvular tissues in subcutaneous spaces. The Biovalves have already achieved satisfactory levels in terms of mechanical properties and valvular functions.
One of our impending challenges in the development of the Biovalves is to improve -9 -the design of the mold and scaffold to achieve more functional and biomimetic structures with the sinus of Valsalva. Moreover, we need to demonstrate the possibility of regeneration and tissue restoration, influence of physical stresses on valvular tissue formation, and adaptability to size discrepancy in vivo, especially in the arterial system. We intend to address these issues through animal implantation experiments. Subsequently, long-term function and tissue reorganization will be investigated in follow-up studies, in addition to the evaluation of surgical safety and the primary function of the Biovalves.
In conclusion, two sizes of in vivo tissue-engineered, autologous, trileaflet, valve-shaped structures known as Biovalves were successfully produced by the in body tissue-architecture technology. This new type bio-added valve prosthesis was, on the whole, satisfactory in terms of valvular functions and mechanical properties. Therefore, the
Biovalves have the potential to be ideal prosthetic heart valves with high biocompatibility and possible to the growth of the recipients recipients' organ. -16 -
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